Immunogenic Cell Death and Metabolic Reprogramming in Cancer: Mechanisms, Synergies, and Innovative Therapeutic Strategies DOI Creative Commons
Jie Jiang, Ying Yan, Chunhui Yang

et al.

Biomedicines, Journal Year: 2025, Volume and Issue: 13(4), P. 950 - 950

Published: April 12, 2025

Immunogenic cell death (ICD) is a promising cancer therapy where dying tumor cells release damage-associated molecular patterns (DAMPs) to activate immune responses. Recent research highlights the critical role of metabolic reprogramming in cells, including Warburg effect, oxidative stress, and lipid metabolism, modulating ICD shaping microenvironment. These changes enhance activation, making tumors more susceptible surveillance. This review explores mechanisms linking mitochondrial endoplasmic reticulum (ER) ferroptosis. It also discusses innovative therapeutic strategies, such as personalized combination therapies, inhibitors, targeted delivery systems, improve efficacy. The future immunotherapy lies integrating activation overcome evasion, with multi-omics approaches microbiome modulation offering new avenues for enhanced treatment outcomes.

Language: Английский

One-step engineered mesenchymal stem cell-derived exosomes against hepatic ischemia–reperfusion injury DOI

Xinfeng Lu,

Haitao Hu, Yujie Zhou

et al.

International Journal of Pharmaceutics, Journal Year: 2025, Volume and Issue: unknown, P. 125292 - 125292

Published: Jan. 1, 2025

Language: Английский

Citations

0
Autologous tumoral esterase-driven therapeutic polymers sequentially orchestrated antigen-induction, STING activation and anti-angiogenesis for systemic cancer immune therapy DOI
Nasha Qiu, Chang Xu, Zhen Zhang

et al.

Biomaterials, Journal Year: 2025, Volume and Issue: unknown, P. 123260 - 123260

Published: March 1, 2025

Language: Английский

Citations

0
Immunogenic Cell Death and Metabolic Reprogramming in Cancer: Mechanisms, Synergies, and Innovative Therapeutic Strategies DOI Creative Commons
Jie Jiang, Ying Yan, Chunhui Yang

et al.

Biomedicines, Journal Year: 2025, Volume and Issue: 13(4), P. 950 - 950

Published: April 12, 2025

Immunogenic cell death (ICD) is a promising cancer therapy where dying tumor cells release damage-associated molecular patterns (DAMPs) to activate immune responses. Recent research highlights the critical role of metabolic reprogramming in cells, including Warburg effect, oxidative stress, and lipid metabolism, modulating ICD shaping microenvironment. These changes enhance activation, making tumors more susceptible surveillance. This review explores mechanisms linking mitochondrial endoplasmic reticulum (ER) ferroptosis. It also discusses innovative therapeutic strategies, such as personalized combination therapies, inhibitors, targeted delivery systems, improve efficacy. The future immunotherapy lies integrating activation overcome evasion, with multi-omics approaches microbiome modulation offering new avenues for enhanced treatment outcomes.

Language: Английский

Citations

0